Monarq Asset Management Announces Strategic Investment From FalconX
NEW YORK, June 2, 2025 /PRNewswire/ -- Monarq Asset Management ("Monarq"), a…
Aon appoints Andy Marcell to serve as CEO of Global Solutions
DUBLIN, June 2, 2025 /PRNewswire/ --Â Aon plc (NYSE: AON), a leading global…
HOTEL101 PROGRESSES TOWARDS NASDAQ LISTING
U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025…
Kia Announces May 2025 Global Sales Results
May 2025 global sales of 269,148 units, up 1.7% Y/yOutside of Korea,…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Vodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and services
Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive…
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term…